Immune and Pancreatic β Cell Interactions in Type 1 Diabetes

Trends in Endocrinology and Metabolism

Volumn 27, Issue 12, 2016, Pages 856-867

  Boldison, Joanne ^a   Wong, F Susan ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

autoimmune disease; immune crosstalk; inflammation; pancreatic islets; type 1 diabetes

Indexed keywords

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL DAMAGE; CELL INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTIC INFILTRATION; MICROENVIRONMENT; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ANIMAL; AUTOIMMUNE DISEASE; IMMUNOLOGY; LYMPHOCYTE; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS; LYMPHOCYTES;

EID: 84999837765     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.08.007     Document Type: Review

References (100)

1. 1 Herold, K.C., et al. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat. Rev. Immunol. 13 (2013), 243–256.
2. 2 Ferris, S.T., et al. Antigen presentation events during the initiation of autoimmune diabetes in the NOD mouse. J. Autoimmun. 71 (2016), 19–25.
3. 3 Klinke, D.J. II, Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One, 3, 2008, e1374.
4. 4 Leete, P., et al. Differential insulitic profiles determine the extent of β-cell destruction and the age at onset of type 1 diabetes. Diabetes 65 (2016), 1362–1369.
5. 5 Wong, F.S., et al. Activation of insulin-reactive CD8 T-cells for development of autoimmune diabetes. Diabetes 58 (2009), 1156–1164.
6. 6 Magnuson, A.M., et al. Population dynamics of islet-infiltrating cells in autoimmune diabetes. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 1511–1516.
7. 7 Friedman, R.S., et al. An evolving autoimmune microenvironment regulates the quality of effector T cell restimulation and function. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 9223–9228.
8. 8 Lindsay, R.S., et al. Antigen recognition in the islets changes with progression of autoimmune islet infiltration. J. Immunol. 194 (2015), 522–530.
9. 9 Diana, J., et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 19 (2013), 65–73.
10. 10 Bosco, D., et al. Unique arrangement of alpha- and beta-cells in human islets of Langerhans. Diabetes 59 (2010), 1202–1210.
11. 11 Rutter, G.A., et al. Pancreatic β-cell identity, glucose sensing and the control of insulin secretion. Biochem. J. 466 (2015), 203–218.
12. 12 Korpos, E., et al. The peri-islet basement membrane, a barrier to infiltrating leukocytes in type 1 diabetes in mouse and human. Diabetes 62 (2013), 531–542.
13. 13 Otonkoski, T., et al. Unique basement membrane structure of human pancreatic islets: implications for beta-cell growth and differentiation. Diabetes Obes. Metab. 10:Suppl. 4 (2008), 119–127.
14. 14 Peiris, H., et al. The β-cell/EC axis: how do islet cells talk to each other?. Diabetes 63 (2014), 3–11.
15. 15 Penko, D., et al. Endothelial progenitor cells enhance islet engraftment, influence β-cell function, and modulate islet connexin 36 expression. Cell Transplant. 24 (2015), 37–48.
16. 16 Hanninen, A., et al. Islet beta-cell-specific T cells can use different homing mechanisms to infiltrate and destroy pancreatic islets. Am. J. Pathol. 170 (2007), 240–250.
17. + T cells. J. Exp. Med. 197 (2003), 643–656.
18. 18 Greening, J.E., et al. Processing and presentation of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T-cells. Diabetes 52 (2003), 717–725.
19. 19 Itoh, N., et al. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J. Clin. Invest. 92 (1993), 2313–2322.
20. 20 Lozanoska-Ochser, B., et al. Expression of CD86 on human islet endothelial cells facilitates T cell adhesion and migration. J. Immunol. 181 (2008), 6109–6116.
21. 21 Thomas, H.E., et al. IFN-γ action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J. Clin. Invest. 102 (1998), 1249–1257.
22. 22 Hamilton-Williams, E.E., et al. Beta cell MHC class I is a late requirement for diabetes. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 6688–6693.
23. + T cells of non-obese diabetic mice. J. Immunol. 151 (1993), 1723–1730.
24. 24 Haskins, K., et al. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 86 (1989), 8000–8004.
25. + T cells to proliferate. Eur. J. Immunol. 45 (2015), 2494–2503.
26. 26 Foulis, A.K., Farquharson, M.A., Aberrant expression of HLA-DR antigens by insulin-containing beta-cells in recent-onset type I diabetes mellitus. Diabetes 35 (1986), 1215–1224.
27. 27 Richardson, S.J., et al. Immunopathology of the human pancreas in type-I diabetes. Semin. Immunopathol. 33 (2011), 9–21.
28. 28 Frigerio, S., et al. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat. Med. 8 (2002), 1414–1420.
29. 29 Eizirik, D.L., et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet., 8, 2012, e1002552.
30. 30 Shioya, M., et al. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas 36 (2008), 197–199.
31. 31 Arif, S., et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 60 (2011), 2112–2119.
32. 32 Singh, B., et al. Immunomodulation and regeneration of islet beta cells by cytokines in autoimmune type 1 diabetes. J. Interferon Cytokine Res. 31 (2011), 711–719.
33. 33 Bachmann, M., et al. IFNα converts IL-22 into a cytokine efficiently activating STAT1 and its downstream targets. Biochem. Pharmacol. 85 (2013), 396–403.
34. 34 Quah, H.S., et al. Deficiency in type I interferon signaling prevents the early interferon-induced gene signature in pancreatic islets but not type 1 diabetes in NOD mice. Diabetes 63 (2014), 1032–1040.
35. 35 Arnush, M., et al. IL-1 produced and released endogenously within human islets inhibits beta cell function. J. Clin. Invest. 102 (1998), 516–526.
36. 36 Arnush, M., et al. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J. Immunol. 160 (1998), 2684–2691.
37. 37 Tai, N., et al. The role of the innate immune system in destruction of pancreatic beta cells in NOD mice and humans with type I diabetes. J. Autoimmun. 71 (2016), 26–34.
38. 38 Ansari, M.J., et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198 (2003), 63–69.
39. −/− mice as an efficient animal model of type I diabetes. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 11823–11828.
40. 40 Hughes, J., et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38 (2015), e55–e57.
41. 41 Carbone, F.R., Tissue-resident memory T cells and fixed immune surveillance in nonlymphoid organs. J. Immunol. 195 (2015), 17–22.
42. + T cells. J. Exp. Med. 196 (2002), 877–886.
43. 43 Calderon, B., Unanue, E.R., Antigen presentation events in autoimmune diabetes. Curr. Opin. Immunol. 24 (2012), 119–128.
44. 44 Calderon, B., et al. Dendritic cells in islets of Langerhans constitutively present beta cell-derived peptides bound to their class II MHC molecules. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 6121–6126.
45. 45 Calderon, B., et al. The central role of antigen presentation in islets of Langerhans in autoimmune diabetes. Curr. Opin. Immunol. 26 (2014), 32–40.
46. 46 Yin, N., et al. Functional specialization of islet dendritic cell subsets. J. Immunol. 188 (2012), 4921–4930.
47. 47 Ferris, S.T., et al. A minor subset of Batf3-dependent antigen-presenting cells in islets of Langerhans is essential for the development of autoimmune diabetes. Immunity 41 (2014), 657–669.
48. 48 Calderon, B., et al. Cellular and molecular events in the localization of diabetogenic T cells to islets of Langerhans. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 1561–1566.
49. 49 Vomund, A.N., et al. Beta cells transfer vesicles containing insulin to phagocytes for presentation to T cells. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E5496–E5502.
50. + DCs. J. Exp. Med. 206 (2009), 3115–3130.
51. + conventional dendritic cells. J. Exp. Med. 207 (2010), 823–836.
52. 52 Calderon, B., et al. The pancreas anatomy conditions the origin and properties of resident macrophages. J. Exp. Med. 212 (2015), 1497–1512.
53. 53 Padgett, L.E., et al. Loss of NADPH oxidase-derived superoxide skews macrophage phenotypes to delay type 1 diabetes. Diabetes 64 (2015), 937–946.
54. 54 Padgett, L.E., et al. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann. N. Y. Acad. Sci. 1281 (2013), 16–35.
55. 55 Allen, J.S., et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 58 (2009), 138–145.
56. 56 Saxena, V., et al. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J. Immunol. 179 (2007), 5041–5053.
57. 57 Pearson, J.A., et al. The importance of the nonobese diabetic (NOD) mouse model in autoimmune diabetes. J. Autoimmun. 66 (2016), 76–88.
58. 58 Lennon, G.P., et al. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 31 (2009), 643–653.
59. 59 Calderon, B., et al. Entry of diabetogenic T cells into islets induces changes that lead to amplification of the cellular response. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 1567–1572.
60. 60 Carrero, J.A., et al. Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouse. PLoS One, 8, 2013, e59701.
61. + T cells infiltrate islets in type 1 diabetes. Diabetes 64 (2015), 172–182.
62. 62 Alkemade, G.M., et al. Local autoantigen expression as essential gatekeeper of memory T-cell recruitment to islet grafts in diabetic hosts. Diabetes 62 (2013), 905–911.
63. 63 Savinov, A.Y., et al. IFN-γ affects homing of diabetogenic T cells. J. Immunol. 167 (2001), 6637–6643.
64. 64 Wong, F.S., et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat. Med. 5 (1999), 1026–1031.
65. + T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J. Immunol. 173 (2004), 6727–6734.
66. 66 Coppieters, K.T., et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 209 (2012), 51–60.
67. 67 Chee, J., et al. Effector-memory T cells develop in islets and report islet pathology in type 1 diabetes. J. Immunol. 192 (2014), 572–580.
68. 68 Graham, K.L., et al. Autoreactive cytotoxic T lymphocytes acquire higher expression of cytotoxic effector markers in the islets of NOD mice after priming in pancreatic lymph nodes. Am. J. Pathol. 178 (2011), 2716–2725.
69. 69 Masopust, D., et al. Stimulation history dictates memory CD8 T cell phenotype: implications for prime–boost vaccination. J. Immunol. 177 (2006), 831–839.
70. 70 McKinney, E.F., et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523 (2015), 612–616.
71. 71 Penaranda, C., et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 12668–12673.
72. + regulatory T-cells of type 1 diabetic subjects. Diabetes 59 (2010), 407–415.
73. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12 (2000), 431–440.
74. 74 Feuerer, M., et al. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 31 (2009), 654–664.
75. 75 Grinberg-Bleyer, Y., et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207 (2010), 1871–1878.
76. 76 Mahne, A.E., et al. Therapeutic regulatory T cells subvert effector T cell function in inflamed islets to halt autoimmune diabetes. J. Immunol. 194 (2015), 3147–3155.
77. 77 Hu, C.Y., et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117 (2007), 3857–3867.
78. 78 Fiorina, P., et al. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 57 (2008), 3013–3024.
79. 79 Wong, F.S., Wen, L., Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes. Rev. Diabet. Stud. 9 (2012), 289–304.
80. 80 Kendall, P.L., et al. Tertiary lymphoid structures in the pancreas promote selection of B lymphocytes in autoimmune diabetes. J. Immunol. 178 (2007), 5643–5651.
81. 81 Kendall, P.L., et al. Peritoneal B cells govern the outcome of diabetes in non-obese diabetic mice. Eur. J. Immunol. 34 (2004), 2387–2395.
82. 82 Puertas, M.C., et al. Phenotype and functional characteristics of islet-infiltrating B-cells suggest the existence of immune regulatory mechanisms in islet milieu. Diabetes 56 (2007), 940–949.
83. 83 Carrillo, J., et al. Islet-infiltrating B-cells in nonobese diabetic mice predominantly target nervous system elements. Diabetes 54 (2005), 69–77.
84. 84 Xiang, Y., et al. The dual effects of B cell depletion on antigen-specific T cells in BDC2.5NOD mice. J. Immunol. 188 (2012), 4747–4758.
85. 85 Serreze, D.V., et al. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes 60 (2011), 2914–2921.
86. + cytotoxic T-cell survival to enhance type 1 diabetes. Diabetes 57 (2008), 909–917.
87. + cells after anti-CD20 treatment in type 1 diabetes in nonobese diabetic mice. J. Immunol. 188 (2012), 294–301.
88. 88 Tian, J., et al. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167 (2001), 1081–1089.
89. 89 Lee, K.M., et al. TGF-β-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance. Eur. J. Immunol. 44 (2014), 1728–1736.
90. + B cells to maintain tolerance to islet autoantigens. Diabetes 64 (2015), 158–171.
91. 91 Wang, R.X., et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 20 (2014), 633–641.
92. 92 Bettini, M., et al. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes 61 (2012), 1519–1526.
93. 93 Xiao, S., et al. Tim-1 is essential for induction and maintenance of IL-10 in regulatory B cells and their regulation of tissue inflammation. J. Immunol. 194 (2015), 1602–1608.
94. 94 Menon, M., et al. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity 44 (2016), 683–697.
95. 95 Mauvais, F.X., et al. Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets. F1000Res., 2016, 10.12688/f1000research.7411.1 Published online April 22, 2016.
96. 96 Pozzilli, P., et al. Combination immunotherapies for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 11 (2015), 289–297.
97. 97 Jayasimhan, A., et al. Advances in our understanding of the pathophysiology of type 1 diabetes: lessons from the NOD mouse. Clin. Sci. (Lond.) 126 (2014), 1–18.
98. 98 Anderson, M.S., Bluestone, J.A., The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23 (2005), 447–485.
99. 99 Willcox, A., et al. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155 (2009), 173–181.
100. 100 Katz, J.D., et al. Following a diabetogenic T cell from genesis through pathogenesis. Cell 74 (1993), 1089–1100.